Marie Skłodowska-Curie Early Stage Researcher (PhD student) in Physico-chemical-biological and in vitro/ in vivo evaluation of anticancer theranostic nanomedicines

The Satchi-Fainaro Research Group at The Tel-Aviv University Faculty of Medicine is looking for an Early Stage Researcher (PhD student) to develop a PhD thesis project on the in vitro and in vivo evaluation of novel anticancer nanomedicines. The contract will be within the framework of the Horizon 2020 Marie Skłodowska-Curie European Training Network THERACAT (H2020-MSCA-ITN-2017-765497), whose objective is to train a new generation of early stage researchers in the field of cancer therapy.

The successful candidate will develop research involving:

– Establish mCherry-labeled orthotopic models of cancer in mice.

– Evaluation of biodistribution of newly-synthesized prodyes.

– Evaluation of anticancer activity of activated prodrugs.

Requirements for candidates:

– B.Sc. and M.Sc. in Chemistry, Biology, Medicine (MD) or Pharmaceutical Sciences (completed before the contract starting date).

– Experience and knowledge in polymer chemistry or tissue culture.

–  Experience and knowledge in using NMR, HPLC/GPC, DLS, and /or CLSM, FACS.

– High motivation and ability to be part of an international multidisciplinary team.

– High level of English and good communication skills.

Marie-Curie fellowship Mobility requirement:

–At the time of recruitment by TAU, candidates must not have resided or carried out their main activity (work or studies) in Israel for more than 12 months in the 3 years immediately prior to their recruitment

We Offer:

– Full time 3 year contract. Very competitive salary. Starting date: From October 1st 2018 to 1st March 2019

– Stimulating, interdisciplinary research and high quality international scientific environment.

For more information on the Satchi-Fainaro Group: http://medicine.mytau.org/satchi-fainaro/

Interested applicants should send their cover letter, CV, full academic record and two references to: ronitsf@tauex.tau.ac.il, before 1/9/2018 (Reference: THERACAT)